Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing ...
The program originated from a joint venture between the two companies that combined Rallybio’s expertise in HPP research with Recursion’s AI platform. Under the agreement, Rallybio will also receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results